201604-0801CI 17. Isshiki T, Sakamoto S, Yamasaki A, et al. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: real-world experience.
Claims-based prevalence of disease progression among patients with fibrosing interstitial lung disease other than idiopathic pulmonary fibrosis in the United States. Ann Am Thorac Soc. 2022;19(7 ...
Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.
The UAB ILD Center offers clinical trial enrollment for patients with idiopathic pulmonary fibrosis and other forms of diffuse parenchymal lung disease as part of a multidisciplinary and integrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback